50 Broadway
7th Floor
London SW1H 0DB
United Kingdom
44 20 7400 3347
https://roivant.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 904
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Matthew Gline | CEO & Director | 1,77M | N/A | 1984 |
Dr. Eric Venker M.D., Pharm.D. | President & COO | 1,28M | N/A | 1987 |
Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 1,72M | N/A | 1976 |
Mr. Richard Pulik | Chief Financial Officer | N/A | N/A | 1979 |
Ms. Rakhi Kumar | Chief Accounting Officer | N/A | N/A | 1980 |
Dr. Huafeng Xu Ph.D. | Chief Technology Officer | N/A | N/A | N/A |
Mr. Jo Chen | General Counsel | N/A | N/A | N/A |
Ms. Kelly Graff | Head of People | N/A | N/A | N/A |
Ms. Marianne L. Romeo | Head of Global Transactions & Risk Management | N/A | N/A | 1968 |
Mr. Alex Gasner | Executive Vice President of Roivant Health | N/A | N/A | N/A |
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
El ISS Governance QualityScore de Roivant Sciences Ltd., a día 1 de mayo de 2024, es 9. Las puntuaciones base son Auditoría: 8; Tablero: 6; Derechos de los accionistas: 3; Compensación: 10.